(Takeda spokesman corrects comment on number of votes neededfor proposal to pass to two thirds from half in 3rd paragraph)
TOKYO, May 29 (Reuters) - Japanese drugmaker TakedaPharmaceutical Co Ltd faces demands from disgruntledshareholders to put to a vote its $62-billion acquisition ofLondon-listed Shire and do more to assuage concerns overthe record-breaking deal.
The deal "carries overly high risks to the company", 12shareholders said in a proposal to be voted on at next month'sannual meeting of shareholders, adding that new shares to beissued to fund the deal threaten "a danger of causing a greatdisadvantage to existing shareholders".
The Shire deal and any future deals worth more than 1trillion yen ($9.19 billion) should be put to a shareholdervote, says the proposal - which will need two thirds of thevotes at the meeting to pass, according to a Takeda spokesman.
Takeda's board of directors opposes the proposal, accordingto the company's notice of convocation that contained theproposal.
The drugmaker already plans to put the Shire deal to a voteat an extraordinary general meeting.($1=108.8300 yen)(Reporting by Sam Nussey;Editing by Clarence Fernandez/Adrian Croft)
